bioRxiv Science⌕ Search

Biology subjects

Dudgeon, T.

Publications and source records attributed to Dudgeon, T..

2 recordsLinked to original sources

The use of a graph database is a complementary approach to a classical similarity search for identifying commercially available fragment merges

AO_SCPLOWBSTRACTC_SCPLOWFragment screening using X-ray crystallography can yield rich structural data to help guide the optimization of low-molecular-weight compounds into more potent binders. Fragment merging, whereby substructural motifs from partially overlapping fragments are incorporated into a single larger compound, represents a potentially powerful and efficient approach for increasing potency. Searching commercial catalogues provides one useful way to quickly and cheaply identify follow-up compounds for purchase and further screening, and circumvents the challenge of synthetic accessibility. The Fragment Network is a graph database that provides a novel way to explore the chemical space surrounding fragment hits. We use an iteration of the database containing >120 million catalogue compounds to find fragment merges for four XChem fragment screening campaigns. Retrieved molecules were filtered using a pipeline of 2D and 3D filters and contrasted against a traditional fingerprint-based similarity search. The two search techniques were found to have complementary results, identifying merges in different regions of chemical space. Both techniques were able to identify merges that are predicted to replicate the interactions made by the parent fragments. This work demonstrates the use of the Fragment Network to increase the yield of fragment merges beyond that of a classical catalogue search, thus increasing the likelihood of finding promising follow-up compounds. We present a pipeline that is able to systematically exploit all known fragment hits by performing large-scale enumeration of all possible fragment pairs for merging.

bioinformatics↗

COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning

We report the results of the COVID Moonshot, a fully open-science, crowd sourced, structure-enabled drug discovery campaign targeting the SARS-CoV-2 main protease. We discovered a non-covalent, non-peptidic inhibitor scaffold with lead-like properties that is differentiated from current main protease inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry. We generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. All compound designs (>18,000 designs), crystallographic data (>840 ligand-bound X-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2,400 compounds) for this campaign were shared rapidly and openly, creating a rich open and IP-free knowledgebase for future anti-coronavirus drug discovery.

biochemistry↗